ONCORADIOMICS
Desconocido
TIGER: Proof of Principle of the best in class therapeutic mRNA cancer vaccine
ONCORADIOMICS
participó en un
H2020:
H2020-SC1-BHC-2018-2020
TIGER delivers proof of principle (PoP) in humans for a novel best-in-class therapeutic mRNA cancer vaccine platform optimized for intraveno...
2021-02-15 - 2025-07-31 | Financiado
2021-02-15 - 2025-07-31 | Financiado
EuCanImage: A European Cancer Image Platform Linked to Biological and Health Data for Next Generation Artificial...
ONCORADIOMICS
participó en un
H2020:
H2020-SC1-FA-DTS-2018-2020
The goal of EuCanImage is to build a highly secure, federated and large-scale European cancer imaging platform, with capabilities that will...
2020-05-29 - 2024-09-30 | Financiado
2020-05-29 - 2024-09-30 | Financiado
PREDICT: A new era in personalised medicine Radiomics as decision support tool for diagnostics and theragnos...
ONCORADIOMICS
participó en un
H2020:
H2020-MSCA-ITN-2017
The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of per...
2017-08-29 - 2022-03-31 | Financiado
2017-08-29 - 2022-03-31 | Financiado
* No se disponen de datos de la empresa actual.